Actively Recruiting
Study of IBI363 in Patients with Advanced First-line Gastric Cancer
Led by Xiangdong Cheng · Updated on 2024-11-20
40
Participants Needed
1
Research Sites
115 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase 1b study designed to evaluate the safety, tolerability and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) in first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.
CONDITIONS
Official Title
Study of IBI363 in Patients with Advanced First-line Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female subjects aged 18 to 75 years
- Diagnosed with unresectable advanced or metastatic gastric or gastroesophageal junction adenocarcinoma without prior systematic treatment
- Have at least one measurable lesion per RECIST v1.1
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Expected survival time of at least 3 months
You will not qualify if you...
- Pregnant or lactating women, or those intending to become pregnant before, during, or within 6 months after the last dose of study drug
- Active uncontrolled bleeding or known bleeding disorders
- History or current active seizure disorder, brain metastases, spinal cord compression, carcinomatous meningitis, or new evidence of brain or leptomeningeal disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
Y
Yanxi Pu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here